A detailed history of Wellington Management Group LLP transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 37,302 shares of KURA stock, worth $336,091. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,302
Previous 44,849 16.83%
Holding current value
$336,091
Previous $923,000 21.13%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$18.57 - $23.23 $140,147 - $175,316
-7,547 Reduced 16.83%
37,302 $728,000
Q2 2024

Aug 13, 2024

BUY
$17.53 - $22.98 $183,661 - $240,761
10,477 Added 30.48%
44,849 $923,000
Q1 2024

May 15, 2024

BUY
$13.42 - $23.53 $461,272 - $808,773
34,372 New
34,372 $733,000
Q4 2023

Feb 12, 2024

BUY
$7.58 - $14.38 $427,231 - $810,499
56,363 New
56,363 $810,000
Q3 2022

Nov 14, 2022

SELL
$12.01 - $19.45 $150,869 - $244,330
-12,562 Reduced 9.12%
125,142 $1.71 Million
Q1 2022

May 16, 2022

SELL
$11.78 - $16.98 $10.7 Million - $15.4 Million
-904,886 Reduced 86.79%
137,704 $2.21 Million
Q4 2021

Feb 11, 2022

BUY
$12.22 - $19.57 $4.13 Million - $6.61 Million
337,672 Added 47.9%
1,042,590 $14.6 Million
Q3 2021

Nov 15, 2021

SELL
$15.42 - $21.72 $21.7 Million - $30.6 Million
-1,409,173 Reduced 66.66%
704,918 $13.2 Million
Q2 2021

Aug 16, 2021

BUY
$20.85 - $29.88 $8.89 Million - $12.7 Million
426,473 Added 25.27%
2,114,091 $44.1 Million
Q1 2021

May 17, 2021

BUY
$24.75 - $39.14 $8.68 Million - $13.7 Million
350,789 Added 26.24%
1,687,618 $47.7 Million
Q4 2020

Feb 12, 2021

BUY
$29.0 - $41.62 $29.9 Million - $42.9 Million
1,030,036 Added 335.74%
1,336,829 $43.7 Million
Q3 2020

Nov 16, 2020

BUY
$16.3 - $30.64 $5 Million - $9.4 Million
306,793 New
306,793 $9.4 Million

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $603M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.